Cargando…

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Adrienne A., Fields, Paul A., Hermine, Olivier, Ramos, Juan C., Beltran, Brady E., Pereira, Juliana, Wandroo, Farooq, Feldman, Tatyana, Taylor, Graham P., Sawas, Ahmed, Humphrey, Jeffrey, Kurman, Michael, Moriya, Junji, Dwyer, Karen, Leoni, Mollie, Conlon, Kevin, Cook, Lucy, Gonsky, Jason, Horwitz, Steven M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518882/ https://www.ncbi.nlm.nih.gov/pubmed/30573506 http://dx.doi.org/10.3324/haematol.2018.205096

Ejemplares similares

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
por: Phillips, Adrienne, et al.
Publicado: (2015)

Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma
por: Bagot, Martine, et al.
Publicado: (2022)

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
por: Horwitz, Steven, et al.
Publicado: (2021)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas
por: Kessler, Linda, et al.
Publicado: (2021)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
por: Trum, Nicholas A., et al.
Publicado: (2021)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
por: Lama, Carine M., et al.
Publicado: (2023)

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review
por: TRAGER, Megan H., et al.
Publicado: (2020)

Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV
por: Boisclair, Stephanie, et al.
Publicado: (2022)

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
por: Caruso, Laura, et al.
Publicado: (2022)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab
por: Wang, Lan, et al.
Publicado: (2020)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)

Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
por: Hirosawa, Makoto, et al.
Publicado: (2022)

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Caribbean Patients With Adult T-Cell Lymphoma/Leukemia at Two Affiliated New York City Hospitals
por: Chiu, Edwin, et al.
Publicado: (2020)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies
por: Zhang, Ting, et al.
Publicado: (2021)

Depletion of central memory CD8(+) T cells might impede the antitumor therapeutic effect of Mogamulizumab
por: Maeda, Yuka, et al.
Publicado: (2021)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

Abscopal Effect After Localized Radiotherapy in a Patient With Sezary Syndrome Under Treatment with Mogamulizumab
por: Grandi, Vieri, et al.
Publicado: (2023)

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-Cell lymphoma
por: Asokan, Ishan, et al.
Publicado: (2021)

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study
por: Jouandet, Marie, et al.
Publicado: (2022)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
por: Ishida, Takashi, et al.
Publicado: (2017)

Commentary to “Mogamulizumab‐induced photosensitivity in patients with mycosis fungoides and other T‐cell neoplasms” by Y. Masuda et al.
por: Hönigsmann, H.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e99aujt8ev66m1nkp834kf1e56